肿瘤细胞治疗研究
英文原题：Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.
Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.
我们开展了一项多中心真实世界队列研究，纳入399例接受BCMA靶向CAR T细胞治疗的RRMM患者，其中348例（87%）接受了桥接治疗。
在BCMA靶向嵌合抗原受体（CAR）T细胞输注时的疾病负荷是复发或难治性多发性骨髓瘤（RRMM）预后的关键决定因素。为预防疾病进展，常在白细胞分离术与输注之间实施桥接治疗，但其临床影响仍不明确。我们开展了一项多中心真实世界队列研究，纳入399例接受BCMA靶向CAR T细胞治疗的RRMM患者，其中348例（87%）接受了桥接治疗。接受桥接治疗的患者疾病更为晚期且生物学特征更差，包括高危细胞遗传学和五药难治性的比例更高。桥接疗效因方案不同而差异显著（P。
Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Bridging therapy is frequently administered between leukapheresis and infusion to prevent disease progression, yet its clinical impact remains unclear. We conducted a multicenter real-world cohort study of 399 patients with RRMM treated with BCMA-directed CAR T-cell therapy, including 348 (87%) who received bridging therapy. Bridging therapy recipients had more advanced and biologically adverse disease, including higher rates of high-risk cytogenetics and penta-class refractoriness. Bridging efficacy varied substantially by regimen (P.
MEMBER ACCOUNT
登录成功会直接打开下一页。
